Arbutus Biopharma Earnings Call Transcripts
Fiscal Year 2024
-
Imdusiran achieved up to 50% functional cure in key HBV patient groups, with strong safety and less frequent dosing than competitors. A phase 2b trial is planned, and the company is well-funded through 2026, with additional pipeline progress and IP litigation ongoing.
-
Promising phase II-A data showed up to 50% functional cure in select hepatitis B patients, with a phase II-B trial and further pipeline updates expected in 2025. Litigation against Moderna and Pfizer could yield substantial financial returns.
-
Imdusiran clinical data show promising antigen loss rates in HBV, especially in patients with low baseline antigen, supporting plans for phase II-B trials. AB-101 demonstrated strong safety and target engagement, with further data expected in 2025. Cash runway extends into Q4 2026.
-
-
The company is advancing a multi-pronged pipeline for hepatitis B, with Imdusiran showing promising phase II results in combination therapies and AB-101 progressing in early trials. Strong financials support ongoing clinical development and patent litigation, with a focus on strategic partnerships for global commercialization.
-
The conference highlighted significant progress in hepatitis B functional cure research, with Imdusiran achieving up to 67% undetectable surface antigen in select patients and strong safety data. Combination trials and a novel PD-L1 inhibitor show promise for future therapies.
-
Positive Phase IIa results for imdusiran combinations support advancement to Phase IIb trials, with operational streamlining extending cash runway into Q4 2026. Six patients achieved sustained undetectable HBV markers, and financials remain strong with $148.5M in cash.
-
The conference highlighted progress in HBV combination therapies, with imdusiran showing a 33% functional cure rate in phase IIa and strong safety. Strategic partnerships and ongoing patent litigation were discussed, with further clinical and legal milestones expected in 2024.